Johnson & Johnson (NYSE:JNJ) Shares Sold by Teachers Retirement System of The State of Kentucky

Share on StockTwits

Teachers Retirement System of The State of Kentucky decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 25.3% during the 2nd quarter, Holdings Channel.com reports. The firm owned 338,151 shares of the company’s stock after selling 114,300 shares during the quarter. Johnson & Johnson accounts for 0.6% of Teachers Retirement System of The State of Kentucky’s investment portfolio, making the stock its 19th biggest holding. Teachers Retirement System of The State of Kentucky’s holdings in Johnson & Johnson were worth $47,554,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Johnson & Johnson by 0.6% during the second quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after purchasing an additional 1,168,129 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Johnson & Johnson by 1.5% during the first quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock valued at $5,100,421,000 after buying an additional 572,077 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 10.8% during the first quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after buying an additional 2,968,879 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Johnson & Johnson by 7.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after buying an additional 2,118,870 shares during the last quarter. Finally, Capital World Investors raised its position in Johnson & Johnson by 182.9% in the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after purchasing an additional 13,703,905 shares in the last quarter. 67.44% of the stock is currently owned by hedge funds and other institutional investors.

In related news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by corporate insiders.

JNJ has been the subject of several recent research reports. Raymond James increased their price target on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the stock from $161.00 to $164.00 in a research report on Monday, July 20th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $168.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $163.00.

Shares of JNJ traded up $0.54 during mid-day trading on Tuesday, hitting $148.89. 3,658,125 shares of the company traded hands, compared to its average volume of 8,477,668. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average of $149.29 and a 200 day moving average of $144.17. The stock has a market capitalization of $392.00 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 3.27 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Thursday, July 16th. The company reported $1.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business had revenue of $18.34 billion for the quarter, compared to analysts’ expectations of $17.73 billion. During the same period in the prior year, the firm earned $2.58 earnings per share. Johnson & Johnson’s revenue was down 10.8% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 7.85 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a dividend of $1.01 per share. The ex-dividend date was Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.71%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: The primary rules of Elliott Wave theory

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.